Tech Company Financing Transactions

Pandion Therapeutics Funding Round

Pandion Therapeutics closed a $80 million Series B funding round on 4/2/2020. Investors included Access Industries, Boxer Capital and BioInnovation.

Transaction Overview

Company Name
Pandion Therapeutics
Announced On
4/2/2020
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors

Access Industries (Lead Investor) (Daniel Becker)

Boxer Capital (Lead Investor) (Christopher Fuglesang)

BioInnovation

JDRF T1D Fund (Jonathan Behr)

OrbiMed

Polaris Partners (Alan Crane)

RA Capital

Roche Venture Fund (Mitchell Mutz)

SR One Capital Management (Vikas Goyal)

Versant Ventures (Carlo Rizzuto)

Proceeds Purpose
Proceeds of the financing will support the continued development of multiple product candidates in Pandion's pipeline, including lead clinical-stage program, PT101, a novel interleukin 2 (IL-2) mutein Fc fusion protein, which is currently in Phase 1 clinical development; bringing a second program into the clinic; and broadening Pandion's modular drug design platform.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
610 Main St.
Cambridge, MA 02139
USA
Phone
(617) 393-5925
Website
www.pandiontx.com
Email Address
[email protected]
Overview
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants.
Profile
Pandion Therapeutics LinkedIn Company Profile
Social Media
Pandion Therapeutics Company Twitter Account
Company News
Pandion Therapeutics News
Facebook
Pandion Therapeutics on Facebook
YouTube
Pandion Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rahul Kakkar
  Rahul Kakkar LinkedIn Profile  Rahul Kakkar Twitter Account  Rahul Kakkar News  Rahul Kakkar on Facebook
Chief Operating Officer
Ed Freedman
  Ed Freedman LinkedIn Profile  Ed Freedman Twitter Account  Ed Freedman News  Ed Freedman on Facebook
Chief Scientific Officer
Jo Viney
  Jo Viney LinkedIn Profile  Jo Viney Twitter Account  Jo Viney News  Jo Viney on Facebook
VP - Bus. Development
Vikas Goyal
  Vikas Goyal LinkedIn Profile  Vikas Goyal Twitter Account  Vikas Goyal News  Vikas Goyal on Facebook
VP - Engineering
Hussam Shaheen
  Hussam Shaheen LinkedIn Profile  Hussam Shaheen Twitter Account  Hussam Shaheen News  Hussam Shaheen on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/2/2020: iTeos Therapeutics venture capital transaction
Next: 4/2/2020: Etailz venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.